Literature DB >> 16181410

Down-regulation of muscarinic acetylcholine receptor M2 adversely affects the expression of Alzheimer's disease-relevant genes and proteins.

Thole Zuchner1, Reinhard Schliebs, J Regino Perez-Polo.   

Abstract

Beta-amyloid peptides play a major role in the pathogenesis of Alzheimer's disease (AD). Therefore, preventing beta-amyloid formation by inhibition of the beta site amyloid precursor protein-cleaving enzyme (BACE) 1 is considered as a potential strategy to treat AD. Cholinergic mechanisms have been shown to control amyloid precursor protein processing and the number of muscarinic M2-acetylcholine receptors is decreased in brain regions of patients with AD enriched with senile plaques. Therefore, the present study investigates the effect of this M2 muscarinic receptor down-regulation by siRNA on total gene expression and on regulation of BACE1 in particular in SK-SH-SY5Y cells. This model system was used for microarray analysis after carbachol stimulation of siRNA-treated cells compared with carbachol stimulated, non-siRNA-treated cells. The same model system was used to elucidate changes at the protein level by using two-dimensional gels followed by Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF) analysis. Taken together, the results indicate that the M2 acetylcholine receptor down-regulation in brains of patients with AD has important effects on the expression of several genes and proteins with major functions in the pathology of AD. This includes beta-secretase BACE1 as well as several modulators of the tau protein and other AD-relevant genes and proteins. Moreover, most of these genes and proteins are adversely affected against the background of AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181410     DOI: 10.1111/j.1471-4159.2005.03335.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

Review 1.  Cholinergic modulation of the hippocampal region and memory function.

Authors:  Juhee Haam; Jerrel L Yakel
Journal:  J Neurochem       Date:  2017-08       Impact factor: 5.372

2.  A population-based study of the association between Trypanosoma cruzi infection and cognitive impairment in old age (the Bambuí Study).

Authors:  M Fernanda Lima-Costa; Erico Castro-Costa; Elizabeth Uchôa; Joselia Firmo; Antonio Luiz P Ribeiro; Cleusa P Ferri; Martin Prince
Journal:  Neuroepidemiology       Date:  2008-12-16       Impact factor: 3.282

Review 3.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

Review 4.  Current Trends of Microfluidic Single-Cell Technologies.

Authors:  Pallavi Shinde; Loganathan Mohan; Amogh Kumar; Koyel Dey; Anjali Maddi; Alexander N Patananan; Fan-Gang Tseng; Hwan-You Chang; Moeto Nagai; Tuhin Subhra Santra
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

5.  Identification of proteins involved in neural progenitor cell targeting of gliomas.

Authors:  Karin Staflin; Thole Zuchner; Gabriella Honeth; Anna Darabi; Cecilia Lundberg
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

6.  Strategies for molecular imaging dementia and neurodegenerative diseases.

Authors:  Bernhard J Schaller
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.